The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

NCT02510261 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Patisiran

Sponsor

Alnylam Pharmaceuticals